Phase 1/2 Study of Vebreltinib (APL-101) in Combination With Osimertinib in Patients With EGFR-mutant Metastatic Non-Small Cell Lung Cancer

Tagrisso (osimertinib) - AstraZeneca

vebreltinib (APL-101) - Apollomics

https://cattendee.abstractsonline.com/meeting/21487/presentation/3035

A. Rohatgi1; B. Patel2; G. Vellequette1; B. Herzog1; J. Ward1; H. Chen1; E. Cali Dylan1; S. Waqar1; N. Wu1; D. Morgensztern1; R. Govindan1; C-T. Yeh3; S. Devarakonda4

Jul 31, 2026